Cover Image

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotinib is non-inferior compared to chemotherapy as a first-line t...

Full description

Saved in:
Bibliographic Details
Main Authors: Heigener, David (Author) , Deppermann, K. M. (Author) , Pawel, J. v. (Author) , Fischer, J. R. (Author) , Kortsik, C. (Author) , Bohnet, S. (Author) , Eiff, M. v. (Author) , Koester, W. (Author) , Thomas, Michael (Author) , Schnabel, Philipp Albert (Author) , Reck, M. (Author)
Format: Article (Journal)
Language:English
Published: 26 January 2014
In: Lung cancer
Year: 2014, Volume: 84, Issue: 1, Pages: 62-66
ISSN:1872-8332
DOI:10.1016/j.lungcan.2014.01.024
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2014.01.024
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500214000609
Get full text
Author Notes:D.F. Heigener, K.M. Deppermann, J. v. Pawel, J.R. Fischer, C. Kortsik, S. Bohnet, M. v. Eiff, W. Koester, M. Thomas, P.A. Schnabel, M. Reck
Description
Summary:Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotinib is non-inferior compared to chemotherapy as a first-line therapy in unselected elderly patients.
Item Description:Gesehen am 26.08.2020
Physical Description:Online Resource
ISSN:1872-8332
DOI:10.1016/j.lungcan.2014.01.024

Similar Items